TY - JOUR
T1 - Addressing Comorbidities in People with Parkinson's Disease
T2 - Considerations From An Expert Panel
AU - Carroll, Camille
AU - Clarke, Carl E.
AU - Grosset, Donald
AU - Rather, Arshad
AU - Mohamed, Biju
AU - Parry, Miriam
AU - Reddy, Prashanth
AU - Fackrell, Robin
AU - Chaudhuri, Kallol Ray
N1 - Publisher Copyright:
© 2024 - The authors. Published by IOS Press.
PY - 2024/1/23
Y1 - 2024/1/23
N2 - In the UK, guidance exists to aid clinicians and patients deciding when treatment for Parkinson's disease (PD) should be initiated and which therapies to consider. National Institute for Health and Care Excellence (NICE) guidance recommends that before starting PD treatment clinicians should discuss the following: the patient's individual clinical circumstances; lifestyle; preferences; needs and goals; as well as the potential benefits and harms of the different drug classes. Individualization of medicines and management in PD significantly improves patients' outcomes and quality of life. This article aims to provide simple and practical guidance to help clinicians address common, but often overlooked, co-morbidities. A multi-disciplinary group of PD experts discussed areas where clinical care can be improved by addressing commonly found co-morbidities in people with Parkinson's (PwP) based on clinical experience and existing literature, in a roundtable meeting organized and funded by Bial Pharma UK Ltd. The experts identified four core areas (bone health, cardiovascular risk, anticholinergic burden, and sleep quality) that, if further standardized may improve treatment outcomes for PwP patients. Focusing on anticholinergic burden, cardiac risk, sleep, and bone health could offer a significant contribution to personalizing regimes for PwP and improving overall patient outcomes. Within this opinion-based paper, the experts offer a list of guiding factors to help practitioners in the management of PwP.
AB - In the UK, guidance exists to aid clinicians and patients deciding when treatment for Parkinson's disease (PD) should be initiated and which therapies to consider. National Institute for Health and Care Excellence (NICE) guidance recommends that before starting PD treatment clinicians should discuss the following: the patient's individual clinical circumstances; lifestyle; preferences; needs and goals; as well as the potential benefits and harms of the different drug classes. Individualization of medicines and management in PD significantly improves patients' outcomes and quality of life. This article aims to provide simple and practical guidance to help clinicians address common, but often overlooked, co-morbidities. A multi-disciplinary group of PD experts discussed areas where clinical care can be improved by addressing commonly found co-morbidities in people with Parkinson's (PwP) based on clinical experience and existing literature, in a roundtable meeting organized and funded by Bial Pharma UK Ltd. The experts identified four core areas (bone health, cardiovascular risk, anticholinergic burden, and sleep quality) that, if further standardized may improve treatment outcomes for PwP patients. Focusing on anticholinergic burden, cardiac risk, sleep, and bone health could offer a significant contribution to personalizing regimes for PwP and improving overall patient outcomes. Within this opinion-based paper, the experts offer a list of guiding factors to help practitioners in the management of PwP.
KW - anticholinergics
KW - bone density
KW - cardiovascular risk
KW - clinical guidelines
KW - individualized treatment
KW - Parkinson's disease
KW - sleep quality
UR - http://www.scopus.com/inward/record.url?scp=85183589503&partnerID=8YFLogxK
U2 - 10.3233/JPD-230168
DO - 10.3233/JPD-230168
M3 - Review article
C2 - 38217610
AN - SCOPUS:85183589503
SN - 1877-7171
VL - 14
SP - 53
EP - 63
JO - Journal of Parkinson's Disease
JF - Journal of Parkinson's Disease
IS - 1
ER -